Deep vein thrombosis and pulmonary embolism: a prospective, observational study to evaluate diagnostic performance of the Tina-quant D-Dimer Gen.2 assay

Affiliation
Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Nuremberg General Hospital, Paracelsus Medical University ,Nuremberg ,Germany
Bertsch, Thomas;
GND
1076402852
Affiliation
Department of Emergency Medicine, Faculty of Medicine, University of Jena
Behringer, Wilhelm;
Affiliation
Emergency Department, University Medical Center Göttingen ,Göttingen ,Germany
Blaschke, Sabine;
Affiliation
Division of Cardiovascular Sciences, Core Technology Facility, University of Manchester ,Manchester ,United Kingdom
Body, Richard;
Affiliation
Roche Diagnostics International Ltd ,Rotkreuz ,Switzerland
Davidson, Simon;
Affiliation
Roche Diagnostics GmbH ,Mannheim ,Germany
Müller-Olling, Mirco;
Affiliation
Roche Diagnostics ,Indianapolis, IN ,United States
Guo, Ge;
Affiliation
Roche Diagnostics GmbH ,Penzberg ,Germany
Rieger, Anna;
Affiliation
Roche Diagnostics GmbH ,Penzberg ,Germany
Wahl, Annika;
Affiliation
Emergency Department, Salford Royal NHS Foundation Trust ,Salford ,United Kingdom
Horner, Daniel;
Affiliation
Roche Diagnostics GmbH ,Penzberg ,Germany
Sun, Yuli;
Affiliation
Agent Representing Roche Diagnostics GmbH ,Penzberg ,Germany
Turnes, Lucia;
Affiliation
Agent Representing Roche Diagnostics GmbH ,Penzberg ,Germany
Sonner, Ulrich;
Affiliation
Roche Diagnostics GmbH ,Penzberg ,Germany
Hoffmann, Michael

Background: D-Dimer testing is a diagnostic tool for exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). This study evaluated the diagnostic performance of the Tina-quant® D-Dimer Gen.2 assay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) in patients with low/intermediate pre-test probability of DVT/PE using standard, age-, and clinical probability-adjusted cut-offs.

Methods: In this prospective, observational, multicenter study (July 2017–August 2019), plasma samples were collected from hospital emergency departments and specialist referral centers. DVT/PE was diagnosed under hospital standard procedures and imaging protocols. A standard D-dimer cut-off of 0.5 µg fibrinogen equivalent units (FEU)/ml was combined with the three-level Wells score; cut-offs adjusted for age (age × 0.01 µg FEU/ml for patients >50 years) and clinical probability (1 µg FEU/ml for low probability) were also evaluated. An assay comparison was conducted in a subset of samples using the Tina-quant D-Dimer Gen.2 assay and the previously established routine laboratory assay, STA-Liatest D-Di Plus assay (Stago Deutschland GmbH, Düsseldorf, Germany).

Results: 2,897 patients were enrolled; 2,516 completed the study (DVT cohort: 1,741 PE cohort: 775). Clinical assessment plus D-dimer testing using the standard cut-off resulted in 317 (DVT) and 230 (PE) false positives, and zero (DVT) and one (PE) false negatives. Negative predictive value (NPV) was 100.0% (95% confidence interval [CI]: 99.7%–100.0%) and 99.8% (95% CI: 98.8%–100.0%) for DVT and PE, respectively. After age-adjustment, NPV was 99.9% (95% CI: 99.6%–100.0%) and 99.1% (95% CI: 97.8–99.7) for DVT and PE, respectively. False positive rates decreased (>50%) in clinical probability-adjusted analyses vs. primary analysis. In the assay comparison, the performances of the two assays were comparable.

Conclusion: The Tina-quant D-Dimer Gen.2 assay and standard D-dimer cut-off level combined with the three-level Wells score accurately identified patients with a very low probability of DVT/PE.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2023 Bertsch, Behringer, Blaschke, Body, Davidson, Müller-Olling, Guo, Rieger, Wahl, Horner, Sun, Turnes, Sonner and Hoffmann.

Use and reproduction: